Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155275 | 1.00 | TACR1 (0.46) | TACR1SIGMAR1TMEM97KMT2AL3MBTL1 | |
| SCHEMBL3158930 | 1.00 | TACR1 (0.46) | TACR1SIGMAR1TMEM97KMT2AL3MBTL1 | |
| SCHEMBL3155279 | 1.00 | TACR1 (0.46) | TACR1SIGMAR1TMEM97KMT2AL3MBTL1 | |
| SCHEMBL3158937 | 1.00 | TACR1 (0.46) | TACR1SIGMAR1TMEM97KMT2AL3MBTL1 | |
| SCHEMBL3161043 | 0.87 | SIGMAR1 (0.48) | TACR1SIGMAR1TMEM97 | |
| SCHEMBL3158902 | 0.87 | SIGMAR1 (0.48) | TACR1SIGMAR1TMEM97 | |
| SCHEMBL3161029 | 0.87 | SIGMAR1 (0.48) | TACR1SIGMAR1TMEM97 | |
| SCHEMBL3158897 | 0.87 | SIGMAR1 (0.48) | TACR1SIGMAR1TMEM97 | |
| SCHEMBL3158912 | 0.87 | SIGMAR1 (0.48) | TACR1SIGMAR1TMEM97 | |
| SCHEMBL29891874 | 0.87 | KMT2A (0.48) | SIGMAR1TMEM97KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1513814-A4 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20050239829-A1 | Novel piperidine compound | TANABE SEIYAKU CO. LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1513814-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099787-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239829-A1 | Novel piperidine compound | EP300, BRD1, CBR3 | TACR1 379/4885SIGMAR1 14/4885TMEM97 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.